Along these lines, it is worth noting that some xCT inhibitors such as SASP have already been approved by FDA for treatment of certain infectious diseases, and its anti-cancer effects are being evaluated in clinical trials (Gout et al., 2001; Robe et al., 2006; Sontheimer and Bridges, 2012). This evidence concerns the gene SLC7A11 and cancer.